Population pharmacokinetics of marbofloxacin in horses: Preliminary analysis

Journal of Veterinary Pharmacology and Therapeutics

Volumn 27, Issue 5, 2004, Pages 283-288

  Peyrou, M ^a   Doucet, Michéle Y ^a   Vrins, A ^a   Concordet, D ^b   Schneider, M ^c   Bousquet Melou A ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CNRS   (France)

^c Magny Vernois ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

MARBOFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXPOSURE; ENTEROBACTERIACEAE; FEMALE; HORSE; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; FEMALE; FLUOROQUINOLONES; GASTRITIS; HORSE DISEASES; HORSES; INJECTIONS, INTRAMUSCULAR; MALE; MASTITIS; QUINOLONES; REGRESSION ANALYSIS; RESPIRATORY TRACT INFECTIONS;

ANIMALIA; ENTEROBACTERIACEAE; EQUIDAE; EQUUS CABALLUS;

EID: 8344234907     PISSN: 01407783     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2004.00591.x     Document Type: Article

References (34)

1. Aliabadi, F.S. & Lees, P. (2002) Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of marbofloxacin in calf serum, exudate and transudate. Journal of Veterinary Pharmacology and Therapeutics, 25, 161-174.
2. Ambrose, P.G. Jr, Owens, R.C. & Grasela, D. (2000) Antimicrobial pharmacodynamics. Medical clinics of North America, 84, 1431-1446.
3. Baggot, J.D. (1980) Distribution of antimicrobial agents in normal and diseased animals. Journal of the American Veterinary Medical Association, 16(10 Spec No), 1085-1090.
4. Barger, A., Fuhst, C. & Wiedemann, B, (2003) Pharmacological indices in antibiotic therapy. Journal of Antimicrobial Chemotherapy, 52, 893-898.
5. Bousquet-Mélou, A., Bernard, S. Schneider, M. & Toutain, P.L. (2002) Pharmacokinetics of marbofloxacin in horses. Equine Veterinary Journal, 34, 366-372.
6. Brown, S.A. (1996) Fluoroquinolones in animal health. Journal of Veterinary Pharmacology and Therapeutics, 19, 1-14.
7. Carretero, M., Rodriguez, C., San Andres, M.I., Fores, P., de Lucas, J.J., Nieto, J., Waxman, S., San Andres, M.D. & Gonzalez, F. (2002) Pharmacokinetics of marbofloxacin in mature horses after single intravenous and intramuscular administration. Equine Veterinary Journal, 34, 360-365.
8. Craig, W.A. (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clinical Infectious Diseases, 26, 1-10.
9. Forrest, A., Nix, D.E., Ballow, C.H., Goss, T.F., Birmingham, M.C. & Schentag, J.J. (1993) Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrobial Agents and Chemotherapy, 37, 1073-1081.
10. Hasegawa, T., Takagi, K. & Kitaichi, K. (1999) Effects of bacterial endotoxin on drug pharmacokinetics. Nagoya Journal of Medical Science, 62, 11-28.
11. Hirata, C.A., Guay, D.R., Awni, W.M., Stein, D.J. & Peterson, P.K. (1989) Steady-state pharmacokinetics of intravenous and oral ciprofloxacin in elderly patients. Antimicrobial Agents and Chemotherapy, 33, 1927-1931.
12. Hyatt, J.M., McKinnon, P.S., Zimmer, G.S. & Schentag, J.J. (1995) The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clinical Pharmacokinetics, 28, 143-160.
13. Jacobs, M.R. (2001) Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clinical microbiology and Infection, 7, 589-596.
14. Lees P. & Shojaee Aliabadi, F. (2002) Marbofloxacin in equine medicine: have we got the dose right? Equine Veterinary Journal, 34, 322-325.
15. Lefebvre, H.P., Schneider, M., Dupouy, V., Laroute, V., Costes, G., Delesalle, L. & Toutain, P.L. (1998) Effect of experimental renal impairment on disposition of marbofloxacin and its metabolites in the dog. Journal of Veterinary Pharmacology and Therapeutics, 21, 453-461.
16. Madaras-Kelly, K.J., Ostergaard, B.E., Hovde, L.B. & Rotschafer, J.C. (1996) Twenty-four-hour area under the concentration-time curve/ MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrobial Agents and Chemotherapy, 40, 627-632.
17. Martin-Jimenez, T. & Riviere, J.E. (1998) Population pharmacokinetics in veterinary medicine: potential use for therapeutic drug monitoring and prediction of tissue residues. Journal of Veterinary Pharmacology and Therapeutics, 21, 167-189.
18. Meinen, J.B., McClure, J.T. & Rosin, E. (1995) Pharmacokinetics of enrofloxacin in clinically normal dogs and mice and drug pharmacodynamics in neutropenic mice with Escherichia coli and staphylococcal infections. American Journal of Veterinary Research, 56, 1219-1224.
19. Monshouwer, M. & Witkamp, R.F. (2000) Cytochromes and cytokines: changes in drug disposition in animals during an acute phase response: a mini-review. The Veterinary Quaterly, 22, 17-20.
20. NCCLS (2002) Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals: Approved Standard-Second Edition. NCCLS document M31-A2. NCCLS, Wayne, Pennsylvania, USA.
21. Post, L.O., Cope, C.V., Farrell, D.E., Baker, J.D. & Myers, M.J. (2002) Influence of porcine Actinobacillus pleuropneumoniae infection and dexamethasone on the pharmacokinetic parameters of enrofloxacin, Journal of Pharmacology and Experimental Therapeutics, 301, 217-222.
22. Post, L.O., Farrell, D.E., Cope, C.V., Baker, J.D. & Myers, M.J. (2003) The effect of endotoxin and dexamethasone on enrofloxacin pharmacokinetic parameters in swine. Journal of Pharmacology and Experimental Therapeutics, 304, 889-895.
23. Preston, S.L., Drusano, G.L., Berman, A.L., Fowler, C.L., Chow, A.T., Dornseif, B., Reichl, V. Natarajan, J. Wong, F.A. & Corrado, M. (1998) Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrobial Agents and Chemotherapy, 42, 1098-1104.
24. Riviere, J.E. (1999) Population pharmacokinetic models and bayesian forecasting applied to clinical pharmacokinetics. In Comparative Pharmacokinetics: Principles, Techniques, and Applications, 1st edn, pp. Ed. Riviere, J. 259-282, Iowa State Press, Ames, IA, USA.
25. Rodvold, K.A. & Neuhauser, M. (2001) Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy, 21(10 Pt 2), 233S-252S.
26. Schentag, J.J., Meagher, A.K. & Forrest. A. (2003) Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials. Annals of Pharmacotherapy, 37, 1478-1488.
27. Schneider, M., Thomas, V., Boisrame, B. & Deleforge, J. (1996) Pharmacokinetics of marbofloxacin in dogs after oral and parenteral administration. Journal of Veterinary Pharmacology and Therapeutics, 19, 56-61.
28. Schneider, M., Vallé, M., Woehrlé, F. & Boisramé, B. (2004) Pharmacokinetics of marbofloxacin in lactating cows after repeated intramuscular administrations and pharmacodynamics against mastitis isolated strains. Journal of Dairy Science, 87, 202-211.
29. Spreng, M., Deleforge, J., Thomas, V., Boisrame, B. & Drugeon, H. (1995) Antibacterial activity of marbofloxacin. A new fluoroquinolone for veterinary use against canine and feline isolates. Journal of Veterinary Pharmacology and Therapeutics, 18, 284-289.
30. Toutain, P.L., Del Castillo, J.R.E. & Bousquet-Mélou, A. (2002) The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics. Research in Veterinary Science, 73, 105-114.
31. Waxman, S., San Andres, M.D., Gonzalez, F., De Lucas, J.J., San Andres, M.I. & Rodriguez, C. (2003) Influence of Escherichia coli endotoxin-induced fever on the pharmacokinetic behavior of marbofloxacin after intravenous administration in goats. Journal of Veterinary Pharmacology and Therapeutics, 26, 65-69.
32. WinNonMix WinNonMix Professional, v 2.0.1. Pharsight corporation. Mountain View, CA, USA.
33. Wright, D.H., Brown, G.H., Peterson, M.L. & Rotschafer, J.C. (2000) Application of fluoroquinolone pharmacodynamics. Journal of Antimicrobial Therapy, 46, 669-683.
34. Zeng, Z.L. & Fung, K.F. (1997) Effects of experimentally induces Escherichia coli infection on the pharmacokinetics of enrofloxacin in pigs. Journal of Veterinary Pharmacology and Therapeutics, 20(Suppl.1), 39-40.